Tirzepatide Phase 3 trial completes investigation into obstructive sleep apnea and obesity
Background
Obstructive sleep apnea (OSA) is a common and serious sleep disorder characterized by recurrent episodes of upper airway collapse during sleep, leading to intermittent hypoxia and sleep fragmentation. It is strongly associated with obesity, which is a chronic disease increasing morbidity and mortality. Current treatments often involve positive airway pressure (PAP) therapy, but adherence can be challenging, and it doesn't address underlying metabolic issues. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for type 2 diabetes and obesity, making it a compelling candidate to investigate for OSA given the strong link between obesity and OSA pathophysiology.
Study Design
This was a Randomized, Double-Blind, Placebo-Controlled Phase 3 Master Protocol trial (NCT05412004) investigating the efficacy and safety of Tirzepatide once weekly in 469 participants with obstructive sleep apnea and obesity. Participants were divided into two main cohorts: those not on positive airway pressure (PAP) therapy and those who were on PAP therapy. Both cohorts received either Tirzepatide or placebo once weekly via subcutaneous (SC) injection for 52 weeks. The Tirzepatide arms involved an initial dose escalation by 2.5 mg every 4 weeks to a maximum tolerated dose (MTD) of 10 mg or 15 mg.
Results
Results from this completed Phase 3 trial are not yet published in the provided abstract, therefore specific findings and numerical outcomes regarding the efficacy and safety of Tirzepatide in obstructive sleep apnea and obesity cannot be reported at this time. The study aimed to investigate the impact of Tirzepatide on participants both with and without positive airway pressure (PAP) therapy over a 52-week period. The primary objective was to assess the efficacy and safety of Tirzepatide in improving OSA severity and related outcomes in this population. The trial completed on March 29, 2024, and the data analysis is presumably underway, with detailed results anticipated in future publications.
Why It Matters
If positive, this trial could represent a significant advancement in the treatment of obstructive sleep apnea, particularly for individuals with co-morbid obesity. Tirzepatide could offer a pharmacological alternative or adjunct to traditional PAP therapy, potentially improving adherence and addressing the underlying metabolic drivers of OSA. This could lead to a new standard of care for obese OSA patients, offering a systemic treatment that tackles both conditions simultaneously. The 52-week duration and inclusion of both PAP-adherent and non-adherent groups mean the findings could be highly relevant for real-world clinical practice, potentially influencing future treatment protocols and guidelines for OSA management.
tirzepatide
obstructive sleep apnea
obesity
phase3
clinical trial
glp-1-agonist